KATHRYN E. FALBERG - 15 Jun 2023 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Director
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
15 Jun 2023
Net transactions value
$0
Form type
4
Filing time
16 Jun 2023, 20:01:59 UTC
Previous filing
30 May 2023
Next filing
12 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Gift $0 -50,504 -56% $0.000000 40,100 15 Jun 2023 Direct F1
transaction RCUS Common Stock Award $0 +6,800 +17% $0.000000 46,900 15 Jun 2023 Direct F2
holding RCUS Common Stock 102,106 15 Jun 2023 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RCUS Stock Option (Right to Buy) Award $0 +19,500 $0.000000 19,500 15 Jun 2023 Common Stock 19,500 $19.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a gift to a family member.
F2 Represents the grant of restricted stock units that vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.
F3 The option will vest in full on the earlier of June 15, 2024 or the next annual meeting of stockholders of the issuer. The option becomes fully vested and exercisable in the event the Company is subject to a change in control.